Tag: KDC-MN-192

  • Milnacipran

    Serotonin-norepinephrine reuptake inhibitor

    An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

    Abstract

    Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.